Phase II study data released for Blautix® in IBS-C and IBS-D

Phase II study data released for Blautix® in IBS-C and IBS-D

4D pharma plc a pharmaceutical company in the development of Live Biotherapeutic products (LBPs) – a novel class of drug derived from the microbiome, today announces additional positive data from its completed Phase II trial of LBP Blautix® in subjects with...
This site is intended for Healthcare Professionals only